Raludotatug Deruxtecan
Phase 2Antibody–drug conjugate
Merck & Co.Raludotatug Deruxtecan is one of 110 biologic programs targeting Ovarian Cancer Recurrent. It is currently in Phase 2.
4
Indications
4
Total Trials
4
Active Trials
109
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
53 competitors in Carcinoma, Non-Small-Cell Lung
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Rybrevant
Johnson & JohnsonPhase 3
Lazcluze
Johnson & JohnsonPhase 3
Imfinzi
AstraZenecaPhase 3
Paraplatin
AAvyxa
Phase 3
Taxol
TevaPhase 3
Tagrisso
AstraZenecaPhase 3
Alimta
EEagle Pharmaceuticals, Inc.
Phase 3
Alimta
SShawn Eagle
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced/Metastatic Solid Tumors1 trial
Intestinal Cancer1 trial
Ovarian Cancer Recurrent1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Raludotatug Deruxtecan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Antibody–drug conjugate[2]
- Highest Phase
- Phase 2[1]
- Company